# A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct01648582` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01648582](<https://clinicaltrials.gov/study/NCT01648582>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01648582

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 774 participants.

## Technical summary

Registry record NCT01648582. Randomized; no masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2015-07-24.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 774 participants (enrolled count; ClinicalTrials.gov record NCT01648582, source copy `cardio:ctgov-nct01648582-2019-09-18`, retrieved 2026-10-26)
- Start date: 2012-07 (registry gives no type) (ClinicalTrials.gov record NCT01648582, source copy `cardio:ctgov-nct01648582-2019-09-18`, retrieved 2026-10-26)
- Primary completion: 2014-08 (actual) (ClinicalTrials.gov record NCT01648582, source copy `cardio:ctgov-nct01648582-2019-09-18`, retrieved 2026-10-26)
- Completion: 2014-12 (actual) (ClinicalTrials.gov record NCT01648582, source copy `cardio:ctgov-nct01648582-2019-09-18`, retrieved 2026-10-26)
- Results first posted: 2015-07-24 (ClinicalTrials.gov record NCT01648582, source copy `cardio:ctgov-nct01648582-2019-09-18`, retrieved 2026-10-26)
- Countries: China; Mexico; Russia; South Korea (ClinicalTrials.gov record NCT01648582, source copy `cardio:ctgov-nct01648582-2019-09-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01648582-2019-09-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus
- Acronym: AWARD-CHN2
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Dulaglutide
- Intervention (Drug): Insulin glargine
- Intervention (Drug): Metformin
- Intervention (Drug): Sulfonylureas
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus (`cardio:pubmed-31950036`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study (`cardio:pubmed-34580638`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 4301bf8d3078f09e78ae0d3082635bd4f1c5cb2c0e789c3a3618ffec6a716cda
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
